Loxo Oncology (LOXO) Reports Q1 Loss of $0.96/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Loxo Oncology Announces First Quarter 2017 Financial Results
May 9, 2017 6:45 AM EDTLarotrectinib Late-Breaking Oral Presentation at ASCO Annual Meeting on June 3, 2017
Company to Host ASCO Conference Call and Webcast on June 4, 2017
$244.3M in Cash, Cash Equivalents, and Investments Provide Runway to Mid-2019
STAMFORD, Conn., May 09, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today reported financial results for the first quarter ended March 31, 2017. Loxo Oncology will not be conducting a conference call in conjunction with this earnings release.
We... More
